PMGC Holdings Inc. (ELAB)
PMGC Holdings Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Newport Beach, CA, US. The stock last traded at $0.89, down 1.22% on the session, giving a market capitalisation of $4.0M. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -873.1%. Its beta of -0.25 implies it has historically moved less than the broad market.
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
PMGC Holdings Inc. is most often compared with the following Healthcare names: